We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Telomere Attrition Blamed for Early Onset Cancer

By Biotechdaily staff writers
Posted on 28 Feb 2007
Cancer researchers have found that telomere shortening is linked to the early development of various types of cancer that characterizes Li-Fraumeni syndrome.

In 1969, Drs. More...
Frederick Li and Joseph Fraumeni first described Li-Fraumeni syndrome (LFS), which is caused by hereditary mutations in the chromosome 17 p53 tumor-suppressor gene. Females with LFS have an increased risk for developing breast cancer, while males and females may also be at risk for developing leukemia, melanoma, colon cancer, pancreatic cancer, brain cancer, and adrenal-corticoid tumors. These cancers often occur at younger ages than are typically observed in the general population, often before age 45. In addition, individuals with a mutation in the p53 gene have a higher risk for developing multiple primary cancers.

Investigators at The Hospital for Sick Children (Toronto, Canada; www.sickkids.ca) analyzed mean telomere length and MDM2-SNP309 polymorphism status in total of 45 peripheral blood lymphocyte samples from 9 LFS families and 15 controls. MDM2 (mouse double minute) is a gene originally identified as amplified in a malignant mouse tumor. It has since been found to be amplified in a number of human cancers including glioblastoma and some osteosarcomas. The gene product of MDM2 is an E3 ubiquitin ligase charged with controlling the levels of the transcription factor p53. Upon binding to MDM2, p53 is ubiquitylated at certain lysine residues, exported from the nucleus, and degraded by the proteasome.

The investigators reported in the February 15, 2007, issue of Cancer Research that telomere length was shorter in carriers with cancer than in healthy carriers and wild-type controls. Within each family, telomere length was shorter in children with cancer than in their healthy siblings and their non-carrier parents. Telomere attrition between children and adults was faster in carriers than in controls. Accelerated telomere attrition in LFS suggested that telomere length could explain earlier age of onset in successive generations of the same family with identical p53/MDM2-SNP309 genotypes.

"We have known since 1990 that Li-Fraumeni was associated with inheritance of a mutated form of the p53 tumor-suppressor gene, but we also noticed each generation developed cancer earlier than the preceding generation,” said senior author Dr. David Malkin, professor of oncology at The Hospital for Sick Children. "By studying blood samples taken from families in which members have Li-Fraumeni, we have discovered that telomeres become shorter in each generation of disease carriers, leading to a genetic instability that primes them for progressively earlier cancers. We were able to look at the DNA of multiple members of families that carried Li-Fraumeni and, overwhelmingly, telomere length was shorter in children with cancer than in unaffected siblings or parents, Children whose telomeres were shorter than their parents who had the disease typically began developing cancer at a much earlier age than their parents.”


Related Links:
The Hospital for Sick Children

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.